Prediabetes market size is estimated to reach USD 360.6 million by the end of 2032. The industry growth is driven by the ...

Rising demand for thiazolidinediones Based on drug class, the prediabetes market size from the thiazolidinediones segment is likely to accelerate at a robust pace between 2024 and 2032.

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

sulfonylureas and thiazolidinediones. Semaglutide was associated with 40% to 70% reduced risks of a first-time Alzheimer’s diagnosis, especially against insulin and even compared to other GLP-1 ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

thiazolidinediones, and other GLP-1RAs (albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide). Their methodology involved using target trial emulation, a type of study that aims to ...

They are also investigating if thiazolidinediones, a class of diabetes drugs, can help to prevent or treat vascular dementia – a common type of dementia caused by reduced blood flow to the brain.

There are numerous trials revealing a blood pressure-lowering effect of thiazolidinediones in diabetic patients as well as in non-diabetic patients. Most of these studies are well designed but ...

or diet and /or exercise therapy with the use of sulfonylureas or thiazolidinediones. • Caution should be taken while prescribing the drug to patients with advanced liver or congestive heart ...

Researchers are investigating whether diabetes and eye disease drugs could also be used to treat or even prevent dementia.

another study - also backed by Alzheimer's Research UK - is investigating whether thiazolidinediones, used to treat diabetes, can help prevent or treat vascular dementia. The condition is known to ...